Galaxy Diagnostics

• ·Galaxy Diagnostics’s last known valuation is $25.0M (Nov 2025).
• ·It has raised $6.8M across 4 recorded rounds; the latest was Seed Round ($3.0M) in May 2026.
• ·Notable investors include Triangle Tweener Fund, Ariel Savannah Angel Partners, BRIDGE Angel Investors, Boston Harbor Angels, First Flight Venture Center — 8 tracked in total.
• ·1 investment vehicle was formed to buy Galaxy Diagnostics shares in the last 12 months, reporting $203K sold to 18 investors, per SEC Form D filings.
• ·Galaxy Diagnostics has filed 5 Form Ds with the SEC since 2009, most recently Apr 2025 ($4.1M sold to 55 investors).
• ·Status: Privately Held (backing).

In the last 12 months, 1 investment vehicle were formed to buy Galaxy Diagnostics shares, reporting $203K sold to 18 investors. Most recent filing May 2026. Vehicles like these are how secondary buyers pool demand for a name; a rising count is a demand signal.

Developer of diagnostic tests intended for early-stage disease detection. The company develops diagnostic tests for various vector-borne diseases such as Bartonellosis and Lyme Disease among others and offers detection for low-abundance flea and tick-borne infections, enabling healthcare providers to have access to advanced tests for disease diagnosis and confirmation in patients.

Sector

Healthcare

HQ

Research Triangle Park, NC, United States

Founded

2009

Employees

19

Website

galaxydx.com/

Ownership

Privately Held (backing)